Heart disease risk tools for women treated for early-stage breast cancer
Developing CVD prediction models for women with early stage breast cancer
This project will build and test tools to predict the chance of heart disease in women who have had early-stage breast cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11261182 on NIH RePORTER |
What this research studies
They will use medical records, treatment history, blood biomarkers, and genetic data from thousands of breast cancer survivors to create two heart-disease risk calculators. The team will combine information about cancer treatments (like anthracyclines), traditional cardiovascular risk factors, and precision cardio-oncology measures to improve predictions. Models will be trained on one group of patients and then validated in separate groups to check accuracy. The goal is to produce tools that doctors can use to tailor heart monitoring and prevention after breast cancer.
Who could benefit from this research
Good fit: Women diagnosed with stage I–III (early-stage) breast cancer, particularly those who received potentially cardiotoxic treatments, are the primary group this work is designed to help.
Not a fit: People without a history of breast cancer, men, or patients with metastatic (stage IV) disease are unlikely to benefit directly from these specific prediction models.
Why it matters
Potential benefit: If successful, the tools could identify breast cancer survivors at high risk for serious heart disease so clinicians can increase monitoring or start preventive care earlier.
How similar studies have performed: Prior research shows biomarkers and genetic data can improve heart-risk prediction generally, but tailored CVD risk calculators specific to breast cancer patients are still new and not yet established.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Greenlee, Heather — Fred Hutchinson Cancer Center
- Study coordinator: Greenlee, Heather
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.